Anafrozi Tablet 250mg (Cefprozil Hydrate)

Adult dose

○ Adults (13 years or older) 1) For pharyngitis and tonsillitis among upper respiratory tract infections, administer cefprozil 500mg (potency) per dose every 24 hours. For acute sinusitis, administer 250mg (potency) or 500mg (potency) every 12 hours (dose escalation is required for moderate or more severe infections). 2) For bacterial secondary infection in acute bronchitis or bacterial exacerbation of chronic bronchitis among lower respiratory tract infections, administer this drug 500mg (potency) per dose every 12 hours. 3) For uncomplicated skin and soft tissue infections, administer this drug 250mg (potency) every 12 hours [or 500mg (potency) every 24 hours], or 500mg (potency) every 12 hours depending on symptoms. 4) For uncomplicated urinary tract infections, administer this drug 500mg (potency) every 24 hours. < Duration of treatment > Treatment is generally given for about 10 days; however, pharyngitis/tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic) should be treated for 10 days or longer. Uncomplicated cystitis is treated for about 7 days. ○ Patients with renal impairment 1) For creatinine clearance of 30～120mL/min, administer according to the standard dosage regimen above. 2) For creatinine clearance of 29mL/min or less, administer 50% of the standard dose at the standard dosing interval. However, some of this drug is removed by hemodialysis; therefore, administer it after the hemodialysis session.

Child dose

○ Children (2～12 years): For pharyngitis and tonsillitis among upper respiratory tract infections, administer 7.5mg (potency) per Kg of body weight per dose every 12 hours. ○ Children (2～12 years): For uncomplicated skin and soft tissue infections, administer 20mg (potency) per Kg of body weight per dose every 24 hours. ○ Infants and children (6 months～12 years): For otitis media among upper respiratory tract infections, administer 15mg per Kg of body weight every 12 hours. ○ Infants and children (6 months～12 years): For acute sinusitis, administer 7.5mg per Kg of body weight every 12 hours. ○ Infants and children (6 months～12 years): For acute sinusitis that is moderate or more severe and requires a dose increase, administer 15mg per Kg of body weight every 12 hours.

This medication is a cephalosporin antibiotic and should not be used in patients with a history of hypersensitivity to cephalosporins. Careful use is required in individuals with a history of allergy to penicillin or other drugs, particularly in patients with renal impairment or severe illness, where renal status should be rigorously evaluated and monitored before and during treatment. Dosing should be adjusted in patients with renal impairment, as drug levels may increase. Patients with gastrointestinal disease or a prior history of colitis should be cautious. Gastrointestinal side effects such as diarrhea, nausea, vomiting, and abdominal pain may occur, and liver function tests may show transient elevations. Allergic reactions such as rash or urticaria may occur, particularly more often reported in children. Central nervous system symptoms like dizziness, headache, and insomnia may rarely occur, and in patients with reduced renal function, there is a risk of seizures, necessitating immediate discontinuation if such symptoms appear. Care must be taken when co-administering this medication with certain antibiotics or diuretics as renal toxicity may increase. It should only be used during pregnancy when absolutely necessary and administered cautiously in breastfeeding, as its effects on infants are unknown. It is advised not to use in infants under 6 months of age, as safety and efficacy have not been established. Elderly patients may require dosage adjustments due to potential renal function decline. This medication may affect certain blood and urine test results, so it is important to inform healthcare professionals during such tests. In cases of overdose in patients with renal impairment, blood dialysis may be performed to remove the medication. To prevent the development of resistant bacteria with prolonged use, it is important to use this medication for the minimum necessary duration, and if signs of non-susceptible bacterial overgrowth or pseudomembranous colitis appear during treatment, immediate consultation with healthcare professionals is required.

• Diarrhea
• nausea
• vomiting
• abdominal pain
• elevated AST
• elevated ALT
• elevated ALP
• elevated bilirubin
• cholestatic jaundice
• rash

This medication should be stored in a light-sensitive container. It should be kept between 1 to 30 degrees Celsius at room temperature to maintain its efficacy and safety.

Appearance

Pale yellow, rectangular film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle